LEADS BIOLABS-B (09887) saw its shares rise more than 4% during the afternoon trading session. At the time of writing, the stock was up 2.28%, trading at HKD 85.3, with a turnover of HKD 37.3549 million. The company recently announced that the first patient has been successfully enrolled in a Phase II clinical study for its self-developed PD-L1/4-1BB bispecific antibody, LBL-024. The study is evaluating the drug in combination therapy as a first-line treatment for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. GF Securities noted in a research report that the registrational Phase IIb study of LBL-024 for third-line or later EP-NEC had completed enrollment of 96 patients by August 2025, with a Biologics License Application expected to be submitted in the third quarter of 2026. The drug candidate has been expanded to 13 solid tumor indications in China and continues to show positive signals in studies for first-line EP-NEC, first-line SCLC, and first-line/second-line or later LNSCLC, with data updates planned for an international conference in 2026. Industrial Securities added that the imminent launch of LBL-024 demonstrates its potential as a blockbuster product.
Comments